181 related articles for article (PubMed ID: 24516212)
1. Cross-boundary cancer studies at the University of Tokyo: Opening a path through research to the future of cancer treatment.
Noda T
Jpn J Clin Oncol; 2014 Feb; 44 Suppl 1():i43-47. PubMed ID: 24516212
[No Abstract] [Full Text] [Related]
2. Cross-boundary cancer studies at the University of Tokyo: Astellas in Asia: challenge for cancer.
Nogimori M
Jpn J Clin Oncol; 2014 Feb; 44 Suppl 1():i60-64. PubMed ID: 24516216
[No Abstract] [Full Text] [Related]
3. Cross-boundary cancer studies at the University of Tokyo: What we can do to overcome cancer.
Kato M
Jpn J Clin Oncol; 2014 Feb; 44 Suppl 1():i48-53. PubMed ID: 24516213
[No Abstract] [Full Text] [Related]
4. Cross-boundary cancer studies at the University of Tokyo: Oncology in Asian countries: clinical development challenges and opportunities.
Rigaudy P
Jpn J Clin Oncol; 2014 Feb; 44 Suppl 1():i54-59. PubMed ID: 24516214
[No Abstract] [Full Text] [Related]
5. GlaxoSmithKline cancer drug threatens Herceptin market.
Waltz E
Nat Biotechnol; 2005 Dec; 23(12):1453-4. PubMed ID: 16333273
[No Abstract] [Full Text] [Related]
6. Association between pharmaceutical involvement and outcomes in breast cancer clinical trials.
Peppercorn J; Blood E; Winer E; Partridge A
Cancer; 2007 Apr; 109(7):1239-46. PubMed ID: 17326054
[TBL] [Abstract][Full Text] [Related]
7. India's drug tests.
Padma TV
Nature; 2005 Jul; 436(7050):485. PubMed ID: 16049471
[No Abstract] [Full Text] [Related]
8. Cancer research in the United States: A critical review of current status and proposal for alternative models.
Kantarjian HM; Prat F; Steensma DP; Kurzrock R; Stewart DJ; Sekeres MA; Leveque J
Cancer; 2018 Jul; 124(14):2881-2889. PubMed ID: 29757456
[No Abstract] [Full Text] [Related]
9. Biomedicine. Pharma firms push for sharing of cancer trial data.
Bhattacharjee Y
Science; 2012 Oct; 338(6103):29. PubMed ID: 23042862
[No Abstract] [Full Text] [Related]
10. Commercial interest waxes for IGF-1 blockers.
Osborne R
Nat Biotechnol; 2008 Jul; 26(7):719-20. PubMed ID: 18612276
[No Abstract] [Full Text] [Related]
11. Discontinued drugs in 2010: oncology drugs.
Williams R
Expert Opin Investig Drugs; 2011 Nov; 20(11):1479-96. PubMed ID: 21955127
[TBL] [Abstract][Full Text] [Related]
12. Cross-boundary cancer studies at the University of Tokyo: Asia as a partner for Japan.
Nishiyama M
Jpn J Clin Oncol; 2014 Feb; 44 Suppl 1():i32-37. PubMed ID: 24516210
[No Abstract] [Full Text] [Related]
13. Fast-forwarding treatment for neurodegenerative disorders.
Mohammadi D
Lancet Neurol; 2015 Jul; 14(7):687-8. PubMed ID: 26067120
[No Abstract] [Full Text] [Related]
14. The Innovative Medicines Initiative: an engine for regulatory science.
Goldman M; Seigneuret N; Eichler HG
Nat Rev Drug Discov; 2015 Jan; 14(1):1-2. PubMed ID: 25503331
[TBL] [Abstract][Full Text] [Related]
15. Clinical setbacks for toll-like receptor 9 agonists in cancer.
Schmidt C
Nat Biotechnol; 2007 Aug; 25(8):825-6. PubMed ID: 17687345
[No Abstract] [Full Text] [Related]
16. Mads Krogsgaard Thomsen. Interview by Asher Mullard.
Thomsen MK
Nat Rev Drug Discov; 2014 Feb; 13(2):96-7. PubMed ID: 24481301
[No Abstract] [Full Text] [Related]
17. Growth industry.
Lewis R
Nature; 2004 Mar; 428(6980):348-9. PubMed ID: 15029202
[No Abstract] [Full Text] [Related]
18. Epidermal growth factor receptor inhibitors: current status and future directions.
Chen HX; Cleck JN; Coelho R; Dancey JE
Curr Probl Cancer; 2009; 33(4):245-94. PubMed ID: 20082842
[No Abstract] [Full Text] [Related]
19. New paradigms for cancer drug discovery.
Sager JA; Lengauer C
Cancer Biol Ther; 2003; 2(4):452-5. PubMed ID: 14508120
[TBL] [Abstract][Full Text] [Related]
20. Big Pharma's Commedia.
Steele FR
Cell; 2005 Dec; 123(6):971-3. PubMed ID: 16360023
[No Abstract] [Full Text] [Related]
[Next] [New Search]
